D. Schrijvers MD, PhD, S. Van Wambeke MD, W. Teurfs MD
The treatment of mRCC has undergone a tremendous evolution in the last decades. There are data that the doublets of checkpoints inhibitors with each other or with anti-angiogenic agents improve PFS compared to sunitinib alone.
In this article, we review the different combinations and give some guidance for their use.
D. Schrijvers MD, PhD, W. Teurfs MD, S. Van Wambeke MD
BRCA mutations play an important role in prostate cancer. All patients with high-risk localised or metastatic prostate cancer should be tested for somatic mutations and, if present, for germline mutations. BRCA muta-tions translate in a more aggressive prostate cancer with a worse prognosis. If these mutations are present, PARP inhibitors may be part of the treatment strategy.